Company Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer.
It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers.
In addition, the company develops IO170, a TGFβ1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
On March 31, 2026, IO Biotech, Inc., along with its affiliate, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | Denmark |
| Founded | 2014 |
| IPO Date | Nov 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Mai-Britt Zocca |
Contact Details
Address: Ole MaalOees Vej 3, Copenhagen N Copenhagen, 2200 Denmark | |
| Phone | 45 70 70 29 80 |
| Website | iobiotech.com |
Stock Details
| Ticker Symbol | IOBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 1865494 |
| CUSIP Number | 449778109 |
| ISIN Number | US4497781090 |
| Employer ID | 87-0909276 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mai-Britt Zocca Ph.D. | Founder, President, Chief Executive Officer, Principal Financial Officer and Director |
| Amy B. Sullivan M.B.A. | Principal Accounting Officer and Chief Financial Officer |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder and Clinical Advisor |
| Prof. Mads Hald Andersen M.D., Ph.D. | Co-Founder and Scientific Advisor |
| Anders Ljungqvist | Founder |
| Prof. Per Thor Straten | Founder |
| Eric Faulkner M.B.A., M.Sc. | Chief Technical Officer |
| Devin Whittemore Smith J.D. | Secretary, General Counsel and Chief Compliance Officer |
| Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Faical Miyara Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2026 | 8-K | Current Report |
| Feb 13, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 6, 2026 | SCHEDULE 13G | Filing |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 23, 2026 | SCHEDULE 13D/A | Filing |
| Jan 21, 2026 | 8-K | Current Report |
| Dec 19, 2025 | 8-K | Current Report |
| Nov 21, 2025 | 8-K | Current Report |
| Nov 18, 2025 | 8-K | Current Report |